Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 287

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Effects of Hydroxyethyl Starch Solutions on Hemostasis

Open access
Kozek-Langenecker, Sibylle A. · 2005 · Anesthesiology

Abstract

HYDROXYETHYL starch (HES) solutions are frequently used plasma expanders that are indicated to restore and maintain intravascular volume, to stabilize hemodynamic conditions, and to improve tissue perfusion. According to these clinical indications, HES is used in perioperative situations with a high risk of bleeding. Side effects of HES on hemostasis pose serious limitations to the clinical use of this artificial colloid. Recent developments have centered around designing new starch molecules by modulating their pharmacochemical characteristics to increase colloid osmotic pressure and hemodynamic efficacy while minimizing the risk of adverse reactions such as antithrombotic effects. The aim of this Clinical Concepts and Commentary article is to provide clinicians with a brief overview of the literature on potential side effects of various HES preparations, including hetastarches, pentastarches, and the novel tetrastarches, on both plasmatic and cellular hemostasis.Polymers of the natural amylopectin are chemically modified by hydroxyethylation at the glucose subunit carbon atoms C2, C3, or C6 (fig. 1). The most important physicochemical characteristics are the molar substitution (mole hydroxyethyl residue per mole glucose subunit), the C2/C6 ratio (pattern of hydroxyethylation at the carbon position C2 and C6), the spectrum of molecular weights, and the mean molecular weight. HES solutions are classified according to the manufactured mean molecular weight into high-molecular-weight (≥ 400 kd), medium-molecular-weight (200–400 kd), and low-molecular-weight solutions (< 200 kd) according to the molar substitution into highly substituted (hetastarch; 0.62–0.75), medium-substituted (pentastarch; 0.5), and the new generation of low-substituted solutions (tetrastarch; 0.4), and according to the C2/C6 ratio into solutions with a high C2/C6 ratio (> 8) or a low C2/C6 ratio (< 8). HESs are polydisperse solutions of molecules with a broad range of molecular weights. After intravenous infusion, the low-molecular-weight fraction is rapidly lost by renal elimination, and the larger molecules are progressively hydrolyzed by serum α-amylase, resulting in a narrow distribution of molecular weights of a mean in vivo molecular weight that is lower than the mean molecular weight of the infused fluid.1α-Amylase, an endo-amylase, cleaves within the polyglucose chain and not glucose-by-glucose from the ends. The resulting smaller HES fragments will be further excreted via urine. A minor proportion is transiently stored in tissues and ultimately excreted after redistribution. Especially molar substitution and C2/C6 ratio determine the in vivo behavior of specific HES types and the rate of HES degradation.1–6Plasma clearance of tetrastarch is at least 20 times higher than that of hetastarch and pentastarch.6Pharmacodynamics regarding volume efficacy are strikingly dependent on the in vivo mean molecular weight and the colloid osmotic pressure.6Similarly, adverse effects on hemostasis are determined by the in vivo degradation of a particular HES preparation. Although methods for determination of the in vivo mean molecular weight have already been validated (low-angle laser light scattering, high-performance liquid chromatography), this clinically relevant information is still lacking in current product information of older HES solutions. Against this background, HES products will be grouped into slowly degradable and rapidly degradable compounds in this review as a surrogate parameter for the in vivo mean molecular weight. High-molecular-weight HES and medium-molecular-weight HES with a high molar substitution are classified as slowly degradable HES; medium-molecular-weight HES with a low molar substitution and low-molecular-weight HES are classified as rapidly degradable HES (table 1). In Europe, a large variety of HES products are commercially available but are dominated by rapidly degradable HES preparations, whereas slowly degradable HES preparations are mainly available in the United States (table 1). Solvents for HES molecules are either saline-based or buffered, balanced electrolyte formulations. Most 6% solutions have a volume expansion of approximately 100%, whereas 10% solutions have an expansion of 130–145% due to the movement of water from the interstitial to the intravascular space. However, statements on volume effects are valid only for selected clinical situations with defined volume status at onset, infusion time, speed, and volumes applied.Maximum daily doses of HES solutions have been recommended to prevent potential side effects. Recent developments center around designing new starch molecules (by modulating molar substitution, molecular weight, and C2/C6 ratio) that not only increase colloid osmotic pressure but also do not interfere with renal function, splanchnic perfusion, reticular endothelial system function, and inflammatory response and do not induce pruritus after long-term and repeated infusion, e.g. ,

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000542-200509000-00031

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 14 references

Cited by

See all 287

Metadata

Authors
Kozek-Langenecker, S. A.
Venue
Anesthesiology
Published
2005-09-01
Volume
103
Issue
3
Pages
654-660
ISSN
0003-3022 (ISSN-L)
OpenAlex
W2047722872
Cited by
287
References
14
FWCI
10.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Hydroxyethyl Starch Solutions on Hemostasis. https://app.cochat.ai/papers/10.1097/00000542-200509000-00031
The paper
Kozek-Langenecker, S. A. (2005). Effects of Hydroxyethyl Starch Solutions on Hemostasis. Anesthesiology. https://doi.org/10.1097/00000542-200509000-00031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.